A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
This is an open label, multi-centre, Phase 1/2 study of BBI503 administered in combination
with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of
the study is to determine the safety, tolerability, and RP2D of BBI503 in combination with
each of the selected anti-cancer agents.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society